Showcased in GEN Magazine's March issue, Biocytogen speaks about the current state and imminent future of animal models, specifically on the humanization of mouse models for complex drug development challenges. Senior vice president of Biocytogen and CEO of Biocytogen Boston Qingcong Lin, PhD is featured alongside executives at Charles River Laboratories, Taconic Biosciences, Jackson Laboratory, and CrownBio Bioscience. Based on current disease treatment demands, scientific community interest, and economic growth valuations, humanized immune checkpoint mice "will become increasingly important tools for in vivo preclinical efficacy studies" in immuno-oncology, setting up companies like Biocytogen that have a growing catalog of double- and triple- humanized models to support the drug discovery process in more ways than before.
